Oncomatryx Announces a €15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment
Following 12 years of pioneering research activities, Oncomatryx is embarking on a new phase in the development of its tumor microenvironment – targeted ADCs. OMTX705, the Crown Jewel, has already proven high antitumor efficacy and unbeatable ADC safety in murine and non-human primate models. Phase I clinical trials in patients suffering metastatic solid tumors will … Read more